Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BY-NCJournal of hepatocellular carcinoma

Prognosis and Safety of Neoadjuvant Therapy Plus Surgery versus Upfront Surgery in Patients with Resectable Hepatocellular Carcinoma at CNLC Ib-IIa Stage: A Propensity Score Matching Study.

  • Bohan Xiang1,2,3
  • Lei Xu1,2,3
  • Jieshen Shan1,2,3
  • Ruizhi Chang1,2,3
  • Qi Ge1,2,3
  • Chendong Wang1,2,3
  • Jia Song1,2,3
  • Xiaoping Chen1,2,3
  • Qiaodan Zhou4
  • Lin Chen1,2,3
4 affiliations
  1. 1Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.
  2. 2Hubei Provincial Clinical Medical Research Center for Liver Surgery, Wuhan, Hubei, 430030, People's Republic of China.
  3. 3Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
  4. 4Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.
Read full textPDFDOICite

Abstract

Introduction

High-level evidence for neoadjuvant therapy in China Liver Cancer Staging (CNLC) Ib-IIa hepatocellular carcinoma (HCC) is lacking, and treatment duration is not standardized. This study aimed to compared prognosis and safety between neoadjuvant therapy plus surgery and upfront surgery, and to explore better neoadjuvant treatment duration, in CNLC Ib-IIa HCC patients.Method

This retrospective study included patients with CNLC stage Ib-IIa HCC who underwent liver resection at our center between 2019 and 2024. Patients were divided into neoadjuvant therapy group and upfront surgery group. Propensity score matching (PSM) was used to control for confounders. In the neoadjuvant therapy group, patients with stable disease (SD) or partial response (PR) after a short course of cycles were subdivided into a short-course group and an extended group. Endpoints were recurrence-free survival (RFS), overall survival (OS), and surgical safety.Results

Of 352 included patients (84 neoadjuvant, 268 upfront surgery), PSM yielded 79 pairs. The neoadjuvant therapy group had longer median RFS (not reached vs 26.5 months; HR 0.48, P < 0.001) and OS (HR 0.48, P < 0.05). Postoperative complications and textbook outcome did not differ. Among the neoadjuvant cohort, the extended group had superior median RFS compared with the short-course group (not reached vs 37.8 months, P = 0.007), with acceptable safety.Conclusions

Preoperative neoadjuvant therapy improves prognosis with acceptable safety in patients with resectable CNLC stage Ib-IIa HCC. In patients with SD/PR after a short course of neoadjuvant therapy, the extended strategy was associated with improved RFS compared with the short-course strategy.

Related

  1. Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis
    Hai Zhang, Yujing Liang, Chaolin Li +3
    Frontiers in medicinePeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  2. Association of 5-hydroxytryptamine 3 receptor antagonists with prognosis in patients with advanced hepatocellular carcinoma: A propensity score-matched study
    Xiaoge Zhang, Xiaoyun Wang, Na Li +2
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologyPLOS
  3. Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design
    Xin Xin, Ruoyu Miao
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  4. The Evolution of Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma: Past Achievements, Current Standards, and Future Perspectives
    Naoto Ujiie, Yusuke Taniyama, Chiaki Sato +5
    CancersPeer-reviewedCC BY 4.0Surgery & anaesthesiaCrossref
  5. Foundation Model-Enabled Pathology-Informed MRI Model for Preoperative Prediction of Vessels Encapsulating Tumor Clusters in Resectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Zhehan Shen, Wanmin Liu, Xiaoming Li +10
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)Peer-reviewedCC BYFull textMedical imaging & radiologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{xiang2026prognosis,
  title = {{Prognosis and Safety of Neoadjuvant Therapy Plus Surgery versus Upfront Surgery in Patients with Resectable Hepatocellular Carcinoma at CNLC Ib-IIa Stage: A Propensity Score Matching Study.}},
  author = {Bohan Xiang and Lei Xu and Jieshen Shan and Ruizhi Chang and Qi Ge and Chendong Wang and Jia Song and Xiaoping Chen and Qiaodan Zhou and Lin Chen},
  journal = {Journal of hepatocellular carcinoma},
  year = {2026},
  month = oct,
  doi = {10.2147/jhc.s653805},
  url = {https://europepmc.org/article/MED/42928896},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Prognosis and Safety of Neoadjuvant Therapy Plus Surgery versus Upfront Surgery in Patients with Resectable Hepatocellular Carcinoma at CNLC Ib-IIa Stage: A Propensity Score Matching Study.
AU  - Bohan Xiang
AU  - Lei Xu
AU  - Jieshen Shan
AU  - Ruizhi Chang
AU  - Qi Ge
AU  - Chendong Wang
AU  - Jia Song
AU  - Xiaoping Chen
AU  - Qiaodan Zhou
AU  - Lin Chen
PY  - 2026
DA  - 2026/10/21
JO  - Journal of hepatocellular carcinoma
DO  - 10.2147/jhc.s653805
UR  - https://europepmc.org/article/MED/42928896
AB  - Introduction  High-level evidence for neoadjuvant therapy in China Liver Cancer Staging (CNLC) Ib-IIa hepatocellular carcinoma (HCC) is lacking, and treatment duration is not standardized. This study aimed to compared prognosis and safety between neoadjuvant therapy plus surgery and upfront surgery, and to explore better neoadjuvant treatment duration, in CNLC Ib-IIa HCC patients.Method  This retrospective study included patients with CNLC stage Ib-IIa HCC who underwent liver resection at our center between 2019 and 2024. Patients were divided into neoadjuvant therapy group and upfront surgery group. Propensity score matching (PSM) was used to control for confounders. In the neoadjuvant therapy group, patients with stable disease (SD) or partial response (PR) after a short course of cycles were subdivided into a short-course group and an extended group. Endpoints were recurrence-free survival (RFS), overall survival (OS), and surgical safety.Results  Of 352 included patients (84 neoadjuvant, 268 upfront surgery), PSM yielded 79 pairs. The neoadjuvant therapy group had longer median RFS (not reached vs 26.5 months; HR 0.48, P < 0.001) and OS (HR 0.48, P < 0.05). Postoperative complications and textbook outcome did not differ. Among the neoadjuvant cohort, the extended group had superior median RFS compared with the short-course group (not reached vs 37.8 months, P = 0.007), with acceptable safety.Conclusions  Preoperative neoadjuvant therapy improves prognosis with acceptable safety in patients with resectable CNLC stage Ib-IIa HCC. In patients with SD/PR after a short course of neoadjuvant therapy, the extended strategy was associated with improved RFS compared with the short-course strategy.
SN  - 2253-5969
ER  -